Prevalence of Delayed Chemotherapy Associated Nausea

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

172 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-29

Study Completion Date

2022-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the prevalence of delayed chemotherapy induced nausea in adult oncology patients in real clinical practice of day clinics.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevalence of Anticipatory Nausea and Vomiting in Cancer Patients Exposed to Highly Emetogenic Chemotherapy

NCT04785495

Chemotherapy-induced Nausea and Vomiting

UNKNOWN

Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting

NCT01993381

Chemotherapy-induced Nausea and Vomiting

UNKNOWN

Incidence and Patterns of Nausea/Vomiting With Combined Chemotherapy and Radiation

NCT00716157

Cancer of the Head and Neck Cancer of the Lung Cancer of the Esophagus +1 more

COMPLETED

Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)

NCT00211601

Chemotherapy Induced Nausea and Vomiting

COMPLETED NA

Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy

NCT01402024

Chemotherapy Induced Nausea and Vomiting

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chemotherapies are rated to have a high to minimal emetogenic potential in oncology patients. Their potential to induce delayed nausea is supposed to often be higher than their emetogenic potential. However, data on delayed chemotherapy-related nausea are scarce, which is problematic because nausea (a) has a large impact on patients quality of life and treatment decisions, (b) is often underestimated by health care professionals, (c) is less responsive to commonly used antiemetic medication, and (d) may even be different from rates that have been established in controlled clinical trials.

Therefore, the aim of this study is to assess the prevalence of delayed chemotherappy-induced nausea in adult oncology patients in dayclinics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chemotherapy-induced Nausea and Vomiting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* first day of chemotherapy of a new cycle (any cycle)
* speak and write German
* sign the consent forms

Exclusion Criteria

* cognitive or linguistic impairments that would significantly impede consent or participation (as assessed by the nurses in charge)
* accompanying radiotherapy;
* pre-existing nausea within three days before the start of the first chemotherapy in this cycle; and
* prior participation in CINrate (each person participates only once)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No